Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Stepping into the sunshine

Nature Biotechnology volume 32, pages 859–862 (2014)Cite this article

Subjects

Is the imminent release of the database of industry's 'gifts' to doctors cause for concern or celebration? Charles Schmidt investigates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Timeline for the roll out of the OPP.

References

  1. Bhandari, M. et al. CMAJ 170, 477–480 (2004).

    PubMed  PubMed Central  Google Scholar 

  2. Borrell, B. A medical Madoff: anesthesiologist faked data in 21 studies. Sci. Am. http://www.scientificamerican.com/article/a-medical-madoff-anesthestesiologist-faked-data/ (10 March 2009).

  3. Harris, G. & Carey, B. NY. Times (Print) Researchers fail to reveal full drug pay. http://www.nytimes.com/2008/06/08/us/08conflict.html?pagewanted=all (8 June 2008).

  4. Vox, F. ProPublica goes after the wrong man in its 'Dollars for Docs' crusades. Forbes http://www.forbes.com/sites/fordvox/2014/04/03/doctor-danger-the-trouble-with-propublicas-dollars-for-docs-crusade/ (3 April 2014).

  5. Ornstein, C. & Jones, R.G. Double dip: doctors paid to advise, promote drug companies that fund their research. The Boston Globe and ProPublicahttp://www.propublica.org/article/double-dip-doctors-paid-to-advise-promote-drug-companies-that-fund-research (25 March 2014).

  6. Seiffert, D. Mass. doctors are getting fewer gifts from drug and device companies. Boston Business Journal http://www.bizjournals.com/boston/blog/bioflash/2014/04/mass-doctors-are-getting-fewer-gifts-from-drug-and.html?page=all (29 April 2014).

  7. Seiffert, D. Bad medicine: why life sciences companies are crying foul over new transparency rules. Boston Business Journal http://www.bizjournals.com/boston/print-edition/2014/06/20/is-transparency-bad-medicine.html?page=all (20 June 2014).

Download references

Author information

Authors and Affiliations

  1. Portland, Maine

    Charles Schmidt

Authors
  1. Charles Schmidt
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmidt, C. Stepping into the sunshine. Nat Biotechnol 32, 859–862 (2014). https://doi.org/10.1038/nbt.3008

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt.3008

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research